BIO — what changed in the latest 10-Q
A section-by-section comparison of BIO's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-11-04 vs the prior 10-Q · 2026-08-04
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +27 | −21 | ~16 | 8 |
| Market risk (Item 3) | Text added/removed | 0 | 0 | ~1 | 0 |
| Controls & procedures | Text added/removed | 0 | 0 | ~1 | 2 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Risk factors | Some risk factors updated | +1 | −1 | ~5 | 85 |
| Other information | Text added/removed | 0 | 0 | ~1 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-11-04
On July 31, 2026, we initiated a new restructuring plan as part of our ongoing program to improve operating performance and strengthen our competitive position, primarily through workforce reductions, consolidation of certain functions and facility closures. We expect to incur total pre-tax costs of…
Once fully implemented, the July 2026 plan is expected to reduce annual operating expenses by $30 million to $35 million by the end of 2027. The estimates of charges or savings could differ materially from actual charges or savings recognized.
During the third quarter of 2026, we recorded restructuring charges of $77.6 million, of which $28.5 million related to the Life Science segment and $49.1 million related to the Clinical Diagnostics segment for the July 2026 plan. See Note 14 in the notes to the condensed consolidated financial stat…
The following table shows Cost of goods sold, Gross profit, components of operating expense, (Gains) losses from change in fair market value of equity securities and loan receivable, Impairment of purchased intangibles and Net income (loss) as a percentage of Net sales:
Selling, general and administrative expense39.2 31.7 35.9 33.0
Text removed vs the prior filing · source: 10-Q · 2026-08-04
The following table shows Cost of goods sold, Gross profit, components of operating expense, (Gains) losses from change in fair market value of equity securities and loan receivable, and Net income (loss) as a percentage of Net sales:
Selling, general and administrative expense32.6 31.9 34.1 33.7
(Gains) losses from change in fair market value of equity securities and loan receivable(70.4)(51.3)22.5 (29.6)
An accounting policy is deemed to be critical if it affects our financial statements materially and requires subjective or complex judgments by management. An accounting estimate is deemed to be critical if it requires assumptions about matters that are highly uncertain at the time the estimate is m…
Consolidated gross margin was 53.1% for the second quarter of 2026 compared to 53.0% for the second quarter of 2025. Gross margin for the Life Science segment for the second quarter of 2026 increased modestly by approximately 0.5 percentage points as compared to the same period in 2025. Gross margin…
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-11-04
competitiveness. See also our risk factors regarding our international operations above and regarding government regulations below.
Text removed vs the prior filing · source: 10-Q · 2026-08-04
decrease in demand for our products, increased competition, downward pressure on prices for our products and longer sales cycles. A weakening of macroeconomic conditions is also adversely affecting our suppliers, which could continue to result in interruptions in the supply of components and raw mat…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice